OSE Immunotherapeutics Receives New US Patent for Tedopi® in Cancer Patients Following Unsuccessful PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
Wednesday, July 05, 2023
OSE Immunotherapeutics has recently been granted a new patent by the United States Patent and Trademark Office, providing protection for their therapeutic cancer vaccine, Tedopi®. This patent specifically covers the use of Tedopi® in HLA-A2 positive patients who have developed secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment. The patent extends the protection for Tedopi® in the US until the year 2037, adding significant value to OSE Immunotherapeutics' product portfolio.
The granted patent acknowledges the innovative nature of utilizing a combination of multiple epitopes, encompassed within Tedopi®, after the failure of PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) patients who are HLA-A2 positive. This patent further strengthens Tedopi® as OSE Immunotherapeutics' leading late-stage asset and underscores its unique value proposition.
This patent represents a significant milestone in the clinical development of Tedopi®, building upon positive results from a Phase 3 trial in NSCLC patients who experienced secondary resistance following checkpoint inhibitor failure. The trial demonstrated notable benefits in overall survival, improved quality of life, and a favorable safety profile compared to chemotherapy. OSE Immunotherapeutics is now preparing for a confirmatory Phase 3 trial that aims to address the high unmet medical need in second-line treatment. Tedopi® differentiates itself through its mechanism of action, activating tumor-specific T cells after acquired resistance to immune checkpoint inhibitors.
Tedopi® is OSE Immunotherapeutics' most advanced product, serving as an off-the-shelf, neoepitope-based immunotherapy. The positive outcomes from the Phase 3 trial (Atalante 1) in non-small cell lung cancer patients who experienced secondary resistance to checkpoint inhibitors have propelled its progress. Additionally, ongoing Phase 2 trials, sponsored by clinical oncology groups, are investigating the use of Tedopi® in combination with other therapies for various solid tumors.